

RECEIVED
CENTRAL FAX CENTER

MAR 25 2008



201 INDUSTRIAL ROAD
SAN CARLOS, CA 94070-6256
(MAIN) 650-631-3100 • (FAX) 650-620-6395

FACSIMILE TRANSMITTAL SHEET

March 25, 2008

TO: **Mail Stop Amendment**
Commissioner for Patents

FROM: Michael J. Mazza
(Reg. No. 30,775)

FAX NO.: (571) 273-8300

TELE. NO.: 650.620.5318
FAX NO.: 650.620.6395

RE: **U.S. Serial No: 10/750,934**
Attorney Docket No.: 0101.00

TOTAL NO. OF PAGES INCLUDING COVER: 17

DOCUMENTS SUBMITTED:

- Transmittal Form (1 page)
- Reply Under 37 C.F.R. §1.111 (15 pages)

Certificate of Facsimile Transmission:

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office, MAIL STOP AMENDMENT, at (571) 273-8300,

on March 25 2008 By: Tina M. Ingrande

Signed Tina M. Ingrande

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is:

1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect phone to the sender named above.

PTO/SB/21 (01-08)

Approved for use through 03/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/750,934
Filing Date	December 31, 2003
First Named Inventor	Thomas E. Tarara
Art Unit	1618
Examiner Name	Leah H. Schlientz
Attorney Docket Number	MAR 25 2008 0101.00

RECEIVED
CENTRAL FAX CENTER


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks It is believed that no fees are due for timely consideration of this paper. In the event that any fees are required, the Commissioner is hereby authorized and requested to charge Deposit Account No. 50-0348.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Nektar Therapeutics		
Signature			
Printed name	Michael J. Mazza		
Date	March 25, 2008	Reg. No.	30,775

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Tina M. Ingrande	Date	03/25/2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 25 2008

PATENT
Attorney Docket No. 0101.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Thomas E. Tarara et al.

APPLICATION NO.: 10/750,934

FILED: December 31, 2003

FOR: PHARMACEUTICAL FORMULATION
WITH AN INSOLUBLE ACTIVE AGENT

EXAMINER: Leah H. Schlientz

ART UNIT: 1618

CONF. NO.: 1899

REPLY UNDER 37 C.F.R. §1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Office Action mailed December 28, 2007, please enter the following amendments and remarks.

In the event that an extension of time is necessary to allow for timely consideration of this paper, such extension is hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to Deposit Account No. 50-0348.

Claims begin on page 2.

Remarks begin on page 11.